CRMD Earnings

CRMD reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 104.00M against an estimate of 86.00M, resulting in a 21.22% surprise. The EPS was 0.57, surpassing the expected 0.48 by 18.75% . The stock experienced a 1.53% price change on the earnings day and a 3.59% change over the next five days, reflecting market reactions to the results.

Following CRMD's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by 1.53% on the day of the release. Over the subsequent five days, it saw a 3.59% change. Historically, CRMD's stock price tends to shift by an average of +1.92% in the 10 days leading up to earnings and +6.86% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CRMD’s annual revenue to reach 128.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 4.76% and EPS estimates Revise Upward by 7.1% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CRMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 4.76%, while EPS estimates moved Revise Upward by 7.1% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CRMD's stock price typically moves by +1.92% in the 10 days before its earnings and +6.86% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 128.00M.

The earnings call summary provides mixed signals. While there are positive aspects such as potential revenue growth from REZZAYO and DefenCath, and expected synergies from the Melinta acquisition, there are concerns about increased operating expenses and lack of clear financial guidance for 2026. The Q&A session reveals some uncertainties, particularly around pricing dynamics post-TDAPA and exact utilization figures for DefenCath. These mixed elements suggest a neutral sentiment, indicating the stock price may remain stable over the next two weeks.